IGLH:高发病率的凝血酶的产生和/或减少血小板反应的妇女有不明原因的月经出血

2018-05-30 MedSci MedSci原创

严重的月经出血(HMB)影响到了20% - 30%的育龄妇女。HMB有一个多因素病理生理学现象,目前对其仍不完全了解。HMB的症状在止血缺陷患者中很常见,同样,月经期大出血的女性,其受损的Von Willebrand因子(VWF)水平和功能、血小板减少、血小板功能受损和凝血功能受损的发生率均较高。本研究的目的是量化在HMB患者中血小板功能受损、凝血功能减弱和VWF活性降低的情况。 研究人员使

严重的月经出血(HMB)影响到了20% - 30%的育龄妇女。HMB有一个多因素病理生理学现象,目前对其仍不完全了解。HMB的症状在止血缺陷患者中很常见,同样,月经期大出血的女性,其受损的Von Willebrand因子(VWF)水平和功能、血小板减少、血小板功能受损和凝血功能受损的发生率均较高。本研究的目的是量化在HMB患者中血小板功能受损、凝血功能减弱和VWF活性降低的情况。

研究人员使用凝血酶生成(TG)、流式细胞术(流式细胞术)和流式细胞术(VWF)功能测试,研究58位女性的止血(中位年龄:48.4岁,40 - 60)HMB。此外,还确定了VWF抗原水平和VWF ristocetin co - factor活性在血小板-弱血浆中的作用。在123名健康志愿者的全血中测量了血小板功能的参考范围,而在126名健康志愿者的血小板血浆(PPP)中测定了TG的参考范围。

结果显示,14(24%)HMB患者血小板功能受损,17(29.3%)患者凝血功能受损。5例患者(8.6%)均有血小板功能受损和凝血功能受损。只有2(3.4%)患者的VWF功能或水平受损,其中一种是与凝血受损同时发生。

研究表明,采用高精密血小板功能测试结合凝血酶产生的方法,可在超过40%的患者中显示凝血功能受损或血小板功能受损。

原始出处:

H. P. Eising, M. Roest, P. , et. al. High prevalence of reduced thrombin generation and/or decreased platelet response in women with unexplained heavy menstrual bleeding

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823463, encodeId=dd57182346377, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Apr 09 07:27:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376803, encodeId=f17a13e6803a4, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jun 01 07:27:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320017, encodeId=2d2532001e84, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed May 30 17:26:50 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320008, encodeId=169432000850, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Wed May 30 16:38:40 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823463, encodeId=dd57182346377, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Apr 09 07:27:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376803, encodeId=f17a13e6803a4, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jun 01 07:27:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320017, encodeId=2d2532001e84, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed May 30 17:26:50 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320008, encodeId=169432000850, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Wed May 30 16:38:40 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
    2018-06-01 luwei00
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823463, encodeId=dd57182346377, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Apr 09 07:27:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376803, encodeId=f17a13e6803a4, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jun 01 07:27:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320017, encodeId=2d2532001e84, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed May 30 17:26:50 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320008, encodeId=169432000850, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Wed May 30 16:38:40 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
    2018-05-30 1e0f8808m18(暂无匿称)

    学习了.谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1823463, encodeId=dd57182346377, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Apr 09 07:27:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376803, encodeId=f17a13e6803a4, content=<a href='/topic/show?id=f8216055671' target=_blank style='color:#2F92EE;'>#月经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60556, encryptionId=f8216055671, topicName=月经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jun 01 07:27:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320017, encodeId=2d2532001e84, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed May 30 17:26:50 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320008, encodeId=169432000850, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Wed May 30 16:38:40 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
    2018-05-30 13718711b3m

    学习了.获益匪浅.感谢分享

    0

相关资讯

Ophthalmologica:视网膜脱离患者的玻璃体视网膜下液体中凝血酶的生成

荷兰鹿特丹眼科医院的Mulder VC近日在Ophthalmologica发表了一篇文章,他们测量了孔源性视网膜脱离(RRD)患者的玻璃体和视网膜下部液体(SRF)中凝血酶原片段(F1 + 2)和凝血酶-抗凝血酶复合物(TAT)的活性,并进一步证实了他们较早之前发现的增生性玻璃体视网膜病变(PVR)患者中凝血酶活性上升。

异常凝血酶原检测超早期发现HBV感染者肝细胞癌1例

患者男性,53岁,2016年6月18日因“腹泻半月”入院。

凝血酶与血凝酶,**不可以弄混!

血凝酶是由巴西矛头蝮蛇(Bothrops Atrox)的蛇毒中分离提纯的。用于需减少流血或止血的医疗情况,可静脉注射、肌肉注射,也可局部使用。凝血酶为牛血或猪血中提取的凝血酶原,经激活而得的无菌冻干品。用于手术中不易结扎的小血管止血、消化道出血及外伤出血等。只能用于局部止血,口服或局部灌注,严禁注射,如误入血管可导致血栓形成、局部坏死危及生命。1、两者到底有多像?两者一般是单支发放。从外表上看两者

IGLH:在餐后脂肪血症期间,VIIaAT复合物、促凝磷脂、凝血酶的产生如何?

活化因子VII在餐后发生激活。部分活化因子VII (VIIa)与抗凝血酶(VIIaAT)形成复合物在体内循环。本研究的主要目是评估餐后脂肪血症对循环的VIIaAT、促凝磷脂(PPL)活性和凝血酶产生的影响。 在标准化口服脂肪耐受性试验(OFTT)中,分别从从后心肌梗死患者(n = 40)和对照组(n = 39)在服药前以及在测试第3和第6小时采集血浆样本。在第2组108例梗死后患者和109例

CCI:达比加群并不能减少STEMI后行直接PCI术患者的梗死面积

HIRIZON-AMI研究是一项大型、前瞻性、随机的急性心肌梗死患者接受再血管化治疗和支架的预后研究。在这项研究中比较了在ST段抬高性心肌梗死患者在直接PCI术后,使用直接凝血酶原抑制剂达比加群与普通肝素加糖蛋白IIb/IIIa受体拮抗剂对全因死亡率和心血管死亡的影响。由于减少大出血事件方面的效应,达比加群组的死亡率较低。但对STEMI患者而言,心肌梗死面积是除了大出血之外的一项影响预后的重要因素